Hansoh (3692.HK) earnings: next date, last results and guidance
When is Hansoh's next earnings date, and what were its last results?
Last results
- SalesRMB8.30 billion+12 %
Hansoh's own figures for the half-year to June 2026. Growth is on a year earlier.
New accounts get one company's ready report free. No card.
Executive summary + 8 chapters · 15,577 words · 134 sources
What has Hansoh guided on medicines and spending?
Management expects to present pivotal study data and submit new drug applications “in due course.” A pivotal Phase III trial is a large, late-stage test designed to give regulators evidence about benefit and safety. Its primary endpoint is the trial’s main pre-agreed question. A BLA is an application to market a biologic medicine.
Management also plans to raise R&D spending and expand hospital coverage. The promise is therefore pipeline progress, which makes the next question whether that progress becomes profitable.
Has Hansoh kept its past promises?
There is evidence of progress against Zhong’s stated strategy. Her 2024 statement emphasised innovation and international licensing. In 2025, she reported three overseas licensing collaborations. She also said innovative medicines and collaborative products exceeded 80% of revenue for the first time. Those are meaningful milestones, but they do not yet prove that the deals will generate durable cash flows.
How have Hansoh’s revenue and profit trended over the last eight quarters?
For the six months ended June 30, 2026, revenue rose 11.7% from the same period in 2025, while profit rose 35.8%. Hansoh attributed the sales increase mainly to innovative medicines and collaborative products. Innovative-medicine revenue represented 85.4% of the half-year total, while oncology supplied 65.9%, confirming the strategic direction but also the continuing concentration.
What should investors watch in Hansoh’s next release?
The most important checkpoints are regulatory decisions and clinical readouts, because either can change the timing and value of future sales.
Questions about Hansoh (3692.HK) earnings
Are Hansoh's latest earnings out?
Yes. Hansoh has reported the half-year to June 2026.
Where could Hansoh stock be by 2029?
Our report's forecast is HK$30.98 a share by October 2029, from the HK$31.74 close of October 16, 2026. Hansoh stock forecast →
More on Hansoh (3692.HK)
Hansoh and its rivals
Hansoh's own filings
This page gives the results. The report gives the reasons.
The full report: an executive summary and 8 chapters, 15,577 words, 26 tables. Its first page opens here, no account needed.
How it is made: AI reads Hansoh's filings, writes the report, checks the numbers against them and cites each source, 134 in this one. How we work · Corrections
Read Hansoh's full report freeNew accounts get one company's ready report free. No card.
Information only, not investment advice. The next results date is an expectation until Hansoh confirms it. Prices are those of the date shown.